HMOX1 and neoplasm: In the control and HMOX1 knockdown groups, bortezomib reduced tumor diameter by 37.7% and 71.9% (fold change 1.91), respectively, and decreased tumor weight by 22.3% and 38.8% (fold change 1.72), respectively.